Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
BHP Shares Fall as Jansen Potash Project Costs Surge 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
BOSTON, Jan. 06, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence J.N. Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 34th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13th, 2016 at 1:30 p.m. PT at The Westin St. Francis in San Francisco, CA.
To access a live audio webcast of the presentation, please visit the Investor Relations section at www.ziopharm.com. The webcast will be archived for 90 days.
About ZIOPHARM Oncology, Inc.:
ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer. The Company's synthetic immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE:XON) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T), natural killer (NK) and T cell receptor (TCR) cell-based approaches that use viral and non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System® technology, a switch to turn on and off, and more precisely modulate gene expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.
Contact: Lori Ann Occhiogrosso ZIOPHARM Oncology, Inc. 617-259-1987 [email protected] David Pitts Argot Partners 212-600-1902 [email protected]
